Credit Suisse: Ditch This Energy Stock

Skepticism is ramping up on SMLP stock

by Karee Venema

Published on Mar 14, 2019 at 1:13 PM

The shares of Summit Midstream Partners LP (NYSE:SMLP) have slumped 4.6% to trade at $9.62 -- fresh off a record low of $9.28 -- after Credit Suisse double-downgraded the energy stock to "underperform" from "outperform," and slashed its price target to $9 from $15. The brokerage firm said the company's fourth-quarter earnings report highlighted "execution issues and funding risks," making it difficult to "justify SMLP's valuation."

Analysts are already skeptical of SMLP stock, with seven of nine covering brokerages maintaining a "hold" or "sell" rating. However, the average 12-month price target of $12 is a 25.3% premium to current levels, meaning there's room for more price-target cuts to come through.

Short sellers have been ramping up their bearish exposure to the equity, too. Short interest rose 22.7% in the two most recent reporting periods to 1.2 million shares. This represents a slim 3% of Summit Midstream Partners' float, meaning there's room for more shorts to climb on board.

While SMLP stock's options pits are typically quiet, volume is buzzing today. While still light on an absolute basis, the 346 calls and 427 puts traded are roughly four and five times what's usually seen at this point, respectively. Some traders appear to be setting a near-term ceiling for the shares, with sell-to-open activity detected at the April 10 call. The $10 level served as a short-term floor for the stock ahead of today's drop, and marked the bottom to its fourth-quarter drop.

smlp stock daily chart march 14


a schaeffer's exclusive

5 HOT STOCK PICKS

Heat up your summer trading with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.
3 Drug Stocks Seeing Unusual Options Trading Today
The FDA approved Sesen's request to move manufacturing for its bladder cancer drug
BofA-Merrill Lynch: Buy This Shoe Stock Before Earnings
The brokerage firm thinks the retailer can rally another 26%
This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.